Terms: = Lymphoma AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Clinical Outcome
22 results:
1. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
[TBL] [Abstract] [Full Text] [Related]
2. runx1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
[TBL] [Abstract] [Full Text] [Related]
3. Effective therapy for AML with runx1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
4. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577
[TBL] [Abstract] [Full Text] [Related]
5. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
6. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.
Guo B; Cen H; Tan X; Ke Q
BMC Med; 2016 Oct; 14(1):159. PubMed ID: 27745550
[TBL] [Abstract] [Full Text] [Related]
7. The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and clinical outcome in Acute Lymphoblastic Leukemia.
Chen D; Zheng J; Gerasimcik N; Lagerstedt K; Sjögren H; Abrahamsson J; Fogelstrand L; Mårtensson IL
PLoS One; 2016; 11(9):e0162638. PubMed ID: 27611867
[TBL] [Abstract] [Full Text] [Related]
8. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract] [Full Text] [Related]
9. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.
Elia L; Grammatico S; Paoloni F; Vignetti M; Rago A; Cenfra N; Mecarocci S; Mancini M; Luciani M; Di Raimondo F; Cazzaniga G; Matarazzo M; Moleti ML; Santoro L; Gaidano G; Foà R; Mandelli F; Cimino G
Am J Hematol; 2011 Dec; 86(12):993-7. PubMed ID: 21953510
[TBL] [Abstract] [Full Text] [Related]
11. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
[TBL] [Abstract] [Full Text] [Related]
13. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract] [Full Text] [Related]
14. Incidence of additional genetic changes in the TEL and aml1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
Stams WA; Beverloo HB; den Boer ML; de Menezes RX; Stigter RL; van Drunen E; Ramakers-van-Woerden NL; Loonen AH; van Wering ER; Janka-Schaub GE; Pieters R
Leukemia; 2006 Mar; 20(3):410-6. PubMed ID: 16424874
[TBL] [Abstract] [Full Text] [Related]
15. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.
Holleman A; den Boer ML; de Menezes RX; Cheok MH; Cheng C; Kazemier KM; Janka-Schaub GE; Göbel U; Graubner UB; Evans WE; Pieters R
Blood; 2006 Jan; 107(2):769-76. PubMed ID: 16189266
[TBL] [Abstract] [Full Text] [Related]
16. Expression levels of TEL, aml1, and the fusion products TEL-aml1 and aml1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract] [Full Text] [Related]
17. High frequency of t(12;21)(p13;q22) in children with acute lymphoblastic leukemia and known clinical outcome in southern Brazil.
Veiga LB; Cóser VM; Cavalli LR; Cavalli IJ; Rodrigues JN; Pereira WV; Pereira DV; Lafayette TC; Villalba BT; Moreira ME; Haddad BR; de Souza Fonseca Ribeiro EM
Leuk Res; 2004 Oct; 28(10):1033-8. PubMed ID: 15289014
[TBL] [Abstract] [Full Text] [Related]
18. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract] [Full Text] [Related]
19. A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia.
Elia L; Mancini M; Moleti L; Meloni G; Buffolino S; Krampera M; De Rossi G; Foà R; Cimino G
Haematologica; 2003 Mar; 88(3):275-9. PubMed ID: 12651265
[TBL] [Abstract] [Full Text] [Related]
20. Analysis of ETV6/aml1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value.
Codrington R; O'Connor HE; Jalali GR; Carrara P; Papaioannou M; Hart SM; Hoffbrand AV; Potter M; Prentice HG; Harrison CJ; Foroni L
Br J Haematol; 2000 Dec; 111(4):1071-9. PubMed ID: 11167742
[TBL] [Abstract] [Full Text] [Related]
[Next]
